



EXPRESS SCRIPTS®

**Express Scripts, Inc.
Pharmacy and Therapeutics Committee
Proceedings
March 20, 2010**

New Drug Evaluations

The Committee reviewed the following new drugs.

- A. **Ampyra™ (dalfampridine extended release tablets) – Acorda Therapeutics/Elan**
- B. **Cayston® (aztreonam for inhalation solution) – Gilead Sciences**
- C. **Pennsaid® (diclofenac sodium topical 1.5% solution) – Covidien/Mallinckrodt/Nuvo**
- D. **Qutenza™ (capsaicin 8% patch) – NeurogesX, Inc.**
- E. **Victoza® (liraglutide [rDNA origin] injection) – NovoNordisk**
- F. **Vpriv™ (velaglucerase alfa for injection) – Shire**
- G. **Xiaflex™ (collagenase clostridium histolyticum for injection, for intralesional use) – Auxilium Pharmaceuticals, Inc.**
- H. **Zirgan™ (ganciclovir ophthalmic gel 0.15%) – Sirion Pharmaceuticals, Inc**

New Indications for Existing Products

The Committee reviewed the following new indications for existing products: [See product inserts for specific wording.]

- A. **Benicar® (olmesartan medoxomil tablets) Sankyo** - For the treatment of hypertension (HTN), either alone or in combination with other antihypertensive agents, in patients 6 to 16 years of age.
- B. **Botox® (onabotulinumtoxin A for injection) Allergan** - Treatment of upper limb spasticity in adult patients, to decrease the severity of increased muscle tone in elbow flexors (biceps), wrist flexors (flexor carpi radialis and flexor carpi ulnaris) and finger flexors (flexor digitorum profundus and flexor digitorum sublimis).
- C. **Crestor® (rosuvastatin calcium tablets) AstraZeneca** - For the primary prevention of cardiovascular disease (CVD). In individuals without clinically evident coronary heart disease but with an increased risk of CVD based on age \geq 50 years old in men and \geq 60 years old in women, hsCRP \geq 2 mg/L, and the presence of \geq one additional CVD risk factor such as hypertension, low HDL-C, smoking, or a family history of premature coronary heart disease, Crestor is indicated to: reduce the risk of stroke, myocardial infarction (MI), and arterial revascularization procedures.
- D. **Cymbalta® (duloxetine hydrochloride delayed release capsules) Eli Lilly** - For the maintenance treatment of generalized anxiety disorder (GAD) in adults.
- E. **Lamictal® XR™ (lamotrigine extended-release tablets) GlaxoSmithKline** - As adjunctive therapy for primary generalized tonic-clonic (PGTC) seizures with or without secondary generalization in patients \geq 13 years of age.
- F. **Patanase® (olopatadine hydrochloride nasal spray) Alcon Laboratories** - For the relief of the symptoms of seasonal allergic rhinitis (SAR) in patients \geq 6 years of age.
- G. **Protonix® (pantoprazole delayed-release tablets and oral suspension) Wyeth** - For the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis in adults and pediatric patients five years of age and older.

- H. **Rituxan[®] (rituximab injection for intravenous use) Genentech/Biogen Idec/Roche** - In combination with fludarabine and cyclophosphamide (FC) for the treatment of patients with previously untreated and previously treated CD20-positive chronic lymphocytic leukemia (CLL).
- I. **Selzentry[®] (maraviroc tablets) Pfizer** - For use in combination with other antiretroviral agents (ARVs) in adult patients infected with only CCR5-tropic HIV-1.
- J. **Seroquel[®] (quetiapine fumarate tablets) AstraZeneca** - For the treatment of schizophrenia in adolescents (13-17 years of age) as monotherapy; and for the acute treatment of manic episodes associated with bipolar I disorder in children and adolescents (10-17 years of age), both as monotherapy and as an adjunct to lithium or divalproex.
- K. **Seroquel XR[®] (quetiapine fumarate extended-release tablets) AstraZeneca.** – For use as adjunctive therapy to antidepressants for the treatment of major depressive disorder.
- L. **Spiriva[®] HandiHaler[®] (tiotropium bromide inhalation powder) Boehringer Ingelheim** - To reduce exacerbations in chronic obstructive pulmonary disease (COPD).
- M. **Tykerb[®] (lapatinib tablets) GlaxoSmithKline** - For use in combination with letrozole (Femara[®]) for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated.
- N. **Zyprexa[®] (olanzapine tablets and orally disintegrating tablets) Eli Lilly** - For the treatment of schizophrenia in adolescents (13-17 years of age) as monotherapy; and for the treatment of manic or mixed episodes associated with bipolar I disorder in adolescents (13-17 years of age) as monotherapy.

New Clinical Line Extensions

The Committee reviewed the following new clinical line extensions.

- A. **Adrenaclick[™] (epinephrine Injection, USP auto-injector) Sciele**
- B. **AllerNaze[™] (triamcinolone acetonide nasal spray) Collegium Pharmaceutical, Inc.**
- C. **Clonidine extended release (ER) oral suspension (no trade name noted) Tris Pharma, Inc.**
- D. **Clonidine extended release (ER) tablet (no trade name noted) Tris Pharma, Inc.**
- E. **Hizentra[®] (Immune globulin subcutaneous [human]), 20% liquid) CSL Behring**
- F. **Lyrica[®] oral solution (pregabalin) Pfizer**
- G. **Menveo[®] (meningococcal [groups A, C, Y, and W-135] oligosaccharide diphtheria CRM197 conjugate vaccine) Novartis**
- H. **Mirapex[®] ER[™] (pramipexole dihydrochloride) extended-release tablets) Boehringer Ingelheim**
- I. **Oleptro[™] (trazodone hydrochloride extended-release tablets) Labopharm, Inc.**
- J. **Omeprazole/ Sodium Bicarbonate/ Magnesium Hydroxide tablets (no trade name noted) Santarus**
- K. **Prevnar[®] 13 (pneumococcal 13-valent conjugate vaccine [diphtheria CRM CRM197 protein]) Wyeth**